Table 3. Summary of 3 and 5-year relapse-free survival (RFS) and breast cancer specific survival (BCSS) comparisons between Cohort A and Cohort B according to study population.
| Population | Number | 3-year RFS | 5-year RFS | HR | P | 3-year BCSS | 5-year BCSS | HR | P |
|---|---|---|---|---|---|---|---|---|---|
| Overall | |||||||||
| Cohort A | 366 | 87.0 | 78.2 | 0.48 | <0.0001 | 96.3 | 93.9 | 0.39 | 0.001 |
| Cohort B | 506 | 95.6 | 89.9 | (0.35-0.67) | 99.3 | 97.4 | (0.21-0.73) | ||
| TP30 | |||||||||
| Cohort A | 214 | 89.4 | 81.4 | 0.60 | 0.02 | 97.1 | 96.6 | 0.63 | 0.26 |
| Cohort B | 314 | 95.6 | 90.7 | (0.39-0.93) | 99.3 | 97.5 | (0.28-1.43) | ||
| TP50 | |||||||||
| Cohort A | 147 | 90.3 | 83.7 | 0.64 | 0.09 | 95.7 | 95.7 | 0.50 | 0.16 |
| Cohort B | 223 | 95.7 | 90.6 | (0.38-1.07) | 100 | 97.4 | (0.19-1.35) |
Abbreviations: Pts, patients; TP 30, triple positive tumors (HER2/ER/PgR-positive) with ER and PgR staining > 30% tumor cells; TP 50, triple positive tumors (HER2/ER/PgR-positive) with ER and PgR staining > 50% tumor cells; HR, hazard ratio.